Panaliti ti Universitas Cincinnati Sakola Kedokteran di Simposium Kanker Taunan on Onkologi Bedah di Chicago tanggal 24 Maret 2018 nunjukkeun yén adjuvant atanapi perawatan tambahan saatos bedah bedah tina jinis tumor gastrointestinal anu jarang henteu ningkatkeun tingkat survival pasien. Papanggihan ieu masihan wawasan anu langkung jero kana pilihan perawatan pikeun jinis pasien kanker ieu, sareng henteu peryogi deui terapi adjuvant anu diresmikeun, ngajaga kualitas kahirupan, sareng nyimpen artos.
Dina ulikan ieu, panalungtik ngagunakeun data tumor tina tahap I nepi ka III penderita ampulla bedah dipiceun ti 1998 nepi ka 2006 (5,298 penderita) dina Kanker Database Nasional Amérika College of Surgeons pikeun ngabandingkeun ukur bedah (3,785), bedah tambah Pasén. kalawan kémoterapi tambahan (316) jeung nu ngalaman bedah tambah kémoterapi tambahan sarta radiotherapy (1,197) dianalisis pikeun survival sakabéh.
29% (1,513) of patients who underwent surgical resection of ampullary tumor received adjuvant therapy. Adjuvant therapy is more commonly used in patients with stage III, lymph node tumors, and positive surgical margins. However, there was no significant difference in stage-specific survival rates among patients with stage I, II, or III receiving any treatment. Similarly, patients with lymph node tumors and positive surgical margins received no adjuvant survival benefit. This national analysis showed that even for patients with aggressive disease, the adjuvant treatment of surgically removed ampullary tumors did not show any survival benefit.
Ku alatan éta, euweuh urusan naon jenis kanker, sagala kanker geus ngembang, perlu pikeun evaluate subtipe kanker sarta béda maranéhanana dina tingkat sélulér. Ngan ngaliwatan tés genetik urang bisa nangtukeun parobahan tingkat molekular pasien jeung pituduh perlakuan leuwih tepat. Analisis atlas multi-platform di Amérika Serikat (perusahaan ubar bimbingan kanker otorisasi di Amérika Serikat) henteu ngan ukur tiasa nganalisis gén supir kanker dina tingkat genetik, tapi ogé ngagabungkeun RNA sareng deteksi protéin pikeun nganalisis mékanisme molekular multi-tingkat, sacara komprehensif. evaluate ciri tumor, sarta comprehensively pituduh nginum obat symptomatic. Inpormasi anu langkung lengkep tiasa ditaroskeun dina Jaringan Oncologist Global.
